VAGISIL ® Lidocaine

VAGISIL ® is a drug based on Lidocaine

THERAPEUTIC GROUP: Antipruriginosi, including antihistamines, anesthetics, etc.

IndicationsAction mechanismStudies and clinical effectiveness Usage and dosage instructionsWarnings Pregnancy and lactationInteractionsContraindicationsUndesirable effects

Indications VAGISIL ® Lidocaine

VAGISIL ® is indicated for the symptomatic treatment of vaginal and perianal itching.

Mechanism of action VAGISIL ® Lidocaine

VAGISIL ® is a medicinal product based on Lidocaine, a local anesthetic that is effective in controlling the activation of peripheral nerve endings, blocking the depolarization of the cell membrane by reducing the permeability to sodium ions.

The aforementioned biological mechanism takes the form of the antipruritic and modestly pain-relieving activity exerted respectively by the depolarization block of type C unmyelinated fibers and nociceptive terminations.

Everything is favored by the good pharmacokinetic properties of Lidocaine applied topically, which make it possible to limit the systemic absorption of the drug and the consequent onset of systemic side effects.

Studies carried out and clinical efficacy

LIDOCAINE IN THE TREATMENT OF THE POST-PARTUM PERIANAL PAIN

Obstet Gynecol. 2002 Dec; 100 (6): 1239-43.

Randomized clinical trial demonstrating that topical 5% Lidocaine treatment is not very effective in treating perianal pain associated with perianal lesions, requiring systemic therapy.

LIDOCAINE IN THE GINEGOLOCIA PRACTICE

J Minim Invasive Gynecol. 2012 May-Jun; 19 (3): 350-5. doi: 10.1016 / j.jmig.2012.01.005. Epub 2012 Mar 13.

Work demonstrating how the application of a 5% Lidocaine cream in post menopausal women can significantly reduce the pain associated with generally painful gynecological diagnostic procedures.

LIDOCAINE TOPIC IN THE TREATMENT OF INJURIES OF ORAL MUCOSA

Clin Oral Investig. 2013 Jul 28. [Epub ahead of print]

Clinical trial demonstrating the clinical efficacy of 2% Lidocaine applied topically in the treatment of oral mucosal lesions in children, resulting significantly more effective than placebo and equally safe and well tolerated.

Method of use and dosage

VAGISIL ®

Gel for cutaneous use at 2% Lidocaine.

Generally, depending on the intensity of the symptoms, it is recommended to apply the appropriate amount of gel on the region to be treated 3-4 times a day, for short periods of time.

Warnings VAGISIL ® Lidocaine

The use of VAGISIL ® should be limited to cases of real need and reduced as much as possible to avoid the unpleasant occurrence of local side effects.

As a local anesthetic, maximum caution is recommended in the application of VAGISIL ® in patients with fungal diseases and elderly patients.

If the use of the medicine does not lead to any kind of improvement in the short term, it would be advisable to immediately consult the doctor with whom to evaluate the possibility of instituting a more suitable therapy.

It is advisable to keep the medicine out of the reach of children.

PREGNANCY AND BREASTFEEDING

Given the complete absence of studies able to best characterize the safety profile of Lidocaine applied topically to the health of the fetus and infant, it would be appropriate to extend the contraindications to the use of VAGISIL ® also to pregnancy and the subsequent period of breastfeeding.

Interactions

Drug interactions worthy of clinical note are not known at the moment, although it is appropriate to consider the ability of propanol and cimetidine to increase plasma Lidocaine levels.

Contraindications VAGISIL ® Lidocaine

The use of VAGISIL ® is contraindicated in patients who are hypersensitive to the active substance or to one of its excipients, in pediatric patients and during pregnancy and lactation.

Undesirable effects - Side effects

The use of VAGISIL ® gel is generally safe and well tolerated, although the inappropriate intake could lead to the onset of local adverse reactions, fortunately of a transitory nature.